- Home
- AKBA vs CRMD Comparison
AKBA vs CRMD Comparison
Compare AKBA & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- CRMD
- Stock Information
- Founded
- AKBA 2007
- CRMD 2006
- Country
- AKBA United States
- CRMD United States
- Employees
- AKBA N/A
- CRMD N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- AKBA Health Care
- CRMD Health Care
- Exchange
- AKBA Nasdaq
- CRMD Nasdaq
- Market Cap
- AKBA 958.6M
- CRMD 877.5M
- IPO Year
- AKBA 2014
- CRMD 2010
- Fundamental
- Price
- AKBA $3.97
- CRMD $11.40
- Analyst Decision
- AKBA Strong Buy
- CRMD Strong Buy
- Analyst Count
- AKBA 5
- CRMD 7
- Target Price
- AKBA $6.90
- CRMD $17.33
- AVG Volume (30 Days)
- AKBA 5.0M
- CRMD 2.4M
- Earning Date
- AKBA 08-07-2025
- CRMD 08-13-2025
- Dividend Yield
- AKBA N/A
- CRMD N/A
- EPS Growth
- AKBA N/A
- CRMD N/A
- EPS
- AKBA N/A
- CRMD 0.28
- Revenue
- AKBA $184,909,000.00
- CRMD $82,553,827.00
- Revenue This Year
- AKBA $26.88
- CRMD $238.38
- Revenue Next Year
- AKBA $44.34
- CRMD $53.52
- P/E Ratio
- AKBA N/A
- CRMD $41.00
- Revenue Growth
- AKBA N/A
- CRMD N/A
- 52 Week Low
- AKBA $0.93
- CRMD $3.61
- 52 Week High
- AKBA $4.08
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- AKBA 62.71
- CRMD 38.32
- Support Level
- AKBA $3.48
- CRMD $11.21
- Resistance Level
- AKBA $3.77
- CRMD $11.74
- Average True Range (ATR)
- AKBA 0.17
- CRMD 0.64
- MACD
- AKBA -0.04
- CRMD -0.45
- Stochastic Oscillator
- AKBA 62.82
- CRMD 2.25
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.